O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+7.9%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$3.98B
AUM Growth
+$3.98B
(-4.5%)
Cap. Flow
-$356M
Cap. Flow
% of AUM
-8.96%
Top 10 Holdings %
Top 10 Hldgs %
49.18%
Holding
122
New
13
Increased
19
Reduced
24
Closed
22
Top Buys
| 1 |
CAI
Caris Life Sciences, Inc. Common Stock
CAI
|
$81.1M |
| 2 |
UnitedHealth
UNH
|
$42.1M |
| 3 |
Roivant Sciences
ROIV
|
$31.3M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$22.4M |
| 5 |
CytomX Therapeutics
CTMX
|
$19.2M |
Top Sells
| 1 |
Pfizer
PFE
|
$97.6M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$76.6M |
| 3 |
Neurocrine Biosciences
NBIX
|
$62.4M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
$41.9M |
| 5 |
Xtant Medical Holdings
XTNT
|
$34.4M |
Sector Composition
| 1 | Healthcare | 99.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
RAPT Therapeutics
RAPT
$187M
| $13.1M | 0.33% |
1,641,906
-11,493,354
| -88% | -$16 |
|
52
Amicus Therapeutics
FOLD
$2.42B
| $13.1M | 0.33% |
2,285,400
| – | – |
|
53
Vir Biotechnology
VIR
$765M
| $12M | 0.3% |
2,380,715
+132,466
| +6% | +$668K |
|
54
AbCellera Biologics
ABCL
$1.19B
| $11.5M | 0.29% |
3,344,568
-836,200
| -20% | -$2.87M |
|
55
Akero Therapeutics
AKRO
$3.65B
| $11.3M | 0.28% |
211,300
+31,400
| +17% | +$1.68M |
|
56
Mineralys Therapeutics
MLYS
$1.94B
| $10.3M | 0.26% |
+760,351
| New | +$10.3M |
|
57
Dyne Therapeutics
DYN
$1.92B
| $9.82M | 0.25% |
1,031,400
+16,789
| +2% | +$160K |
|
58
C4 Therapeutics
CCCC
$182M
| $9.77M | 0.24% |
6,830,300
| – | – |
|
59
Oric Pharmaceuticals
ORIC
$1.03B
| $9.13M | 0.23% |
899,281
+199,281
| +28% | +$2.02M |
|
60
Catalyst Pharmaceutical
CPRX
$2.42B
| $9.05M | 0.23% |
+416,900
| New | +$9.05M |
|
61
Prelude Therapeutics
PRLD
$69.1M
| $8.83M | 0.22% |
10,909,256
| – | – |
|
62
Corbus Pharmaceuticals
CRBP
$121M
| $8.09M | 0.2% |
1,172,287
| – | – |
|
63
Zai Lab
ZLAB
$3.48B
| $8.08M | 0.2% |
+231,000
| New | +$8.08M |
|
64
Tarsus Pharmaceuticals
TARS
$2.44B
| $8.02M | 0.2% |
197,900
-455,843
| -70% | -$18.5M |
|
|
WHWK
65
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$85.3M
| $7.79M | 0.19% |
4,166,000
| – | – |
|
66
Tyra Biosciences
TYRA
$657M
| $7.7M | 0.19% |
804,603
-948,228
| -54% | -$9.07M |
|
67
Adicet Bio
ACET
$60.8M
| $6.98M | 0.17% |
11,447,140
| – | – |
|
|
ITOS
68
DELISTED
iTeos Therapeutics
ITOS
| $6.98M | 0.17% |
+700,000
| New | +$6.98M |
|
69
PMV Pharmaceuticals
PMVP
$82.1M
| $6.86M | 0.17% |
6,475,291
| – | – |
|
70
UroGen Pharma
URGN
$896M
| $6.55M | 0.16% |
+478,400
| New | +$6.55M |
|
71
Ascendis Pharma
ASND
$12.1B
| $5.94M | 0.15% |
+34,400
| New | +$5.94M |
|
|
ALMS
72
Alumis Inc. Common Stock
ALMS
$483M
| $5.78M | 0.14% |
+1,926,423
| New | +$5.78M |
|
|
JBIO
73
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $5.31M | 0.13% |
+531,163
| New | +$5.31M |
|
74
InspireMD
NSPR
$101M
| $4.84M | 0.12% |
2,133,405
| – | – |
|
75
Avalo Therapeutics
AVTX
$139M
| $4.83M | 0.12% |
967,000
| – | – |
|